Endpoints News 生物医药· Kyle LaHucik·· 2026-10-09AI 评分43
Viatris将以16.5亿美元现金收购Pacira BioSciences,加码非阿片类疼痛药物
Viatris to make $1.65B Pacira acquisition, adding to momentum in pain
AI 导读
仿制药与品牌药生产商Viatris将以16.5亿美元现金收购商业化阶段的Pacira BioSciences,由此进入非阿片类疼痛药物领域。交易于周四上午宣布。
正文
Viatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences.
The Thursday morning deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news